Yiming Guan, Yu Luan, Shanshan Zhao, Meiyan Li, Francesco Girolamo, Joshua D Palmer, Qi Guan
{"title":"Single-cell RNA sequencing for characterizing the immune communication and iron metabolism roles in CD31<sup>+</sup> glioma cells.","authors":"Yiming Guan, Yu Luan, Shanshan Zhao, Meiyan Li, Francesco Girolamo, Joshua D Palmer, Qi Guan","doi":"10.21037/tcr-2025-377","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gliomas are aggressive brain tumors marked by complex cellular interactions and significant immune cell infiltration. This study investigated the role of CD31<sup>+</sup> immune cells, specifically macrophages and T cells, in the glioma microenvironment through single-cell RNA sequencing (scRNA-seq).</p><p><strong>Methods: </strong>We employed the CellChat framework to map cell-cell communication pathways and used Monocle3 for pseudotime trajectory analysis to characterize the signaling and developmental progressions within CD31<sup>+</sup> cells. Pathways such as osteopontin (SPP1) and major histocompatibility complex class II (MHC-II) were analyzed in terms of their role in immune regulation, and we examined the expression of ferritin, an iron-binding protein, to assess its potential function in modulating CD31<sup>+</sup> cell activity.</p><p><strong>Results: </strong>Our findings highlight the expression of key pathways, including SPP1 and MHC-II, influencing immune regulation. Ferritin was found to be highly expressed in CD31<sup>+</sup> cells, suggesting a dual role in iron metabolism and immune modulation within the glioma microenvironment.</p><p><strong>Conclusions: </strong>This study clarified the distinct roles of CD31<sup>+</sup> immune cells in glioma progression and identified ferritin as a potential therapeutic target for modulating immune responses in gliomas. These findings may offer new directions in glioma research and the development of immunotherapy, which can aid in improving treatment outcomes.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 4","pages":"2421-2439"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079608/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2025-377","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gliomas are aggressive brain tumors marked by complex cellular interactions and significant immune cell infiltration. This study investigated the role of CD31+ immune cells, specifically macrophages and T cells, in the glioma microenvironment through single-cell RNA sequencing (scRNA-seq).
Methods: We employed the CellChat framework to map cell-cell communication pathways and used Monocle3 for pseudotime trajectory analysis to characterize the signaling and developmental progressions within CD31+ cells. Pathways such as osteopontin (SPP1) and major histocompatibility complex class II (MHC-II) were analyzed in terms of their role in immune regulation, and we examined the expression of ferritin, an iron-binding protein, to assess its potential function in modulating CD31+ cell activity.
Results: Our findings highlight the expression of key pathways, including SPP1 and MHC-II, influencing immune regulation. Ferritin was found to be highly expressed in CD31+ cells, suggesting a dual role in iron metabolism and immune modulation within the glioma microenvironment.
Conclusions: This study clarified the distinct roles of CD31+ immune cells in glioma progression and identified ferritin as a potential therapeutic target for modulating immune responses in gliomas. These findings may offer new directions in glioma research and the development of immunotherapy, which can aid in improving treatment outcomes.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.